I somewhat share Baldwidx concerns that we may have a potential issue with NNZ-2591 development, being that we do not have complete control over what indications can be developed for NNZ-2591 on our own.From the NEU announcement 14/7/2023;
Neuren has an obligation not to develop NNZ-2591 or any other product for North America in an indication for which Acadia develops trofinetide, except for Phelan-McDermid, Pitt Hopkins, Angelman and Prader-Willi syndromes.
If Acadia decide to begin to developing trofinetide across an expansive range of syndromes how will that affect NNZ-2591's value?
I can't answer whether or not they can they do that, or whether they would they do that, or even if Acadia could afford to, however it certainly bares considering.
I somewhat share Baldwidx concerns that we may have a potential...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.150(0.74%) |
Mkt cap ! $2.566B | |||
| Open | High | Low | Value | Volume |
| $20.40 | $20.50 | $19.88 | $4.961M | 246.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 277 | $20.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.15 | 2400 | 1 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.12 |
Change
-0.150 ( 0.58 %) |
||||
| Open | High | Low | Volume | ||
| $20.45 | $20.50 | $19.88 | 139634 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| NEU (ASX) Chart |